Cairo - Mubasher: Ibnsina Pharma recorded consolidated net profits after tax worth EGP 951.98 million in 2025, which reflected a year-on-year (YoY) surge from EGP 614.56 million.
The earnings per share (EPS) grew to EGP 0.76 in January-December 2025 from EGP 0.49 a year earlier, according to the financial results.
Net sales reached EGP 76.59 billion at the end of 2025 when compared with EGP 55.84 billion in 2024.
Standalone Results
The EGX-listed company logged higher non-consolidated net profits after tax at EGP 920.72 million as of 31 December 2025, versus EGP 620.52 million in the previous year.
Standalone net revenues hiked YoY to EGP 76.28 billion in 2025 from EGP 55.65 billion, while the EPS climbed to EGP 0.74 from EGP 0.50.
In January 2026, the European Bank for Reconstruction and Development (EBRD) announced the extension of an EGP 1.30 billion loan to Ibnsina Pharma to finance green capital expenditure for a new warehouse and related long-term working capital.
